SARM1-Mediated NAD+ Depletion as Terminal Executor of MCT1-Dependent Axon Degeneration

Target: SARM1, NMNAT2 Composite Score: 0.614 Price: $0.61▼0.8% Citation Quality: Pending neurodegeneration Status: promoted
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
🧠 Neurodegeneration
✓ All Quality Gates Passed
Quality Report Card click to collapse
B
Composite: 0.614
Top 8% of 512 hypotheses
T5 Contested
Contradicted by evidence, under dispute
B+ Mech. Plausibility 15% 0.70 Top 49%
C+ Evidence Strength 15% 0.58 Top 60%
A Novelty 12% 0.85 Top 30%
C+ Feasibility 12% 0.55 Top 56%
B+ Impact 12% 0.72 Top 44%
B Druggability 10% 0.65 Top 44%
B Safety Profile 8% 0.60 Top 37%
A Competition 6% 0.80 Top 31%
C+ Data Availability 5% 0.50 Top 71%
C+ Reproducibility 5% 0.55 Top 62%
Evidence
6 supporting | 6 opposing
Citation quality: 0%
Debates
2 sessions B+
Avg quality: 0.73
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

What is the molecular mechanism by which oligodendroglial MCT1 disruption causes axon damage and neuron loss?

The study shows that MCT1 disruption leads to axon degeneration and neuron death, but the specific molecular pathways linking lactate transport dysfunction to neuronal damage remain unexplained. Understanding this mechanism is critical for developing targeted neuroprotective therapies. Gap type: unexplained_observation Source paper: Oligodendroglia metabolically support axons and contribute to neurodegeneration. (2012, Nature, PMID:22801498)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (1)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Parvalbumin Interneuron Vulnerability Links Lactate Transport to Gamma Oscillation Dysfunction
Score: 0.569 | Target: PVALB, SLC16A1/MCT1

→ View full analysis & all 2 hypotheses

Description

MCT1 disruption creates lactate transport deficiency that depletes axonal NAD+ via SARM1 activation, triggering feed-forward NAD+ destruction analogous to Wallerian degeneration.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.70 (15%) Evidence 0.58 (15%) Novelty 0.85 (12%) Feasibility 0.55 (12%) Impact 0.72 (12%) Druggability 0.65 (10%) Safety 0.60 (8%) Competition 0.80 (6%) Data Avail. 0.50 (5%) Reproducible 0.55 (5%) 0.614 composite
12 citations 12 with PMID Validation: 0% 6 supporting / 6 opposing
Evidence Matrix — sortable by strength/year, click Abstract to expand
ClaimTypeSourceStrength ↕Year ↕PMIDsAbstract
NMNAT2 is a druggable target to drive neuronal NAD…Supporting---PMID:39048544-
SARM1-specific motifs enable NAD+ loss and regulat…Supporting---PMID:27671644-
Caspase-3 cleaves and activates NADase SARM1 to pr…Supporting---PMID:41576094-
Hyperglycemia promotes SARM1 activation via SIRT3-…Supporting---PMID:41512034-
Small molecule SARM1 inhibitors allow recovery of …Supporting---PMID:33406435-
WLD(S) protein partially rescues mitochondrial res…Supporting---PMID:25352062-
MCT1 knockout phenotypes are late-onset (6-12 mont…Opposing---PMID:33440165-
SARM1 knockout mice show normal development and ba…Opposing---PMID:31689415-
SARM1 primary activation trigger is DAMPs and calc…Opposing---PMID:31689415-
NMNAT2 has short half-life (~30-60 min) making sus…Opposing---PMID:39048544-
Temporal NAD+ measurement shows NAD+ depletion occ…Opposing---PMID:31689415-
Alternative mechanisms (AMPK activation, primary m…Opposing---PMID:31689415-
Legacy Card View — expandable citation cards

Supporting Evidence 6

NMNAT2 is a druggable target to drive neuronal NAD production
SARM1-specific motifs enable NAD+ loss and regulate injury-induced activation
Caspase-3 cleaves and activates NADase SARM1 to promote apoptosis
Hyperglycemia promotes SARM1 activation via SIRT3-mediated deacetylation
Small molecule SARM1 inhibitors allow recovery of metastable axon pool
WLD(S) protein partially rescues mitochondrial respiration after axonal injury

Opposing Evidence 6

MCT1 knockout phenotypes are late-onset (6-12 months), inconsistent with rapid SARM1 activation timeline
SARM1 knockout mice show normal development and baseline neural function
SARM1 primary activation trigger is DAMPs and calcium influx, not energy depletion
NMNAT2 has short half-life (~30-60 min) making sustained pharmacological enhancement difficult
Temporal NAD+ measurement shows NAD+ depletion occurs after structural markers, not before
Alternative mechanisms (AMPK activation, primary myelin instability, calcium dysregulation) may predominate
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-14 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Mechanistically-Specific Hypotheses: MCT1 Disruption → Neuronal Damage

Hypothesis 1: SIRT3-Mediated Mitochondrial NAD+ Depletion Drives Distal Axon Degeneration

Title: SIRT3 NAD+ Loss Triggers Axon Degeneration

Mechanism: MCT1 disruption in oligodendrocytes reduces lactate delivery to axons, impairing neuronal pyruvate oxidation and NAD+ regeneration. SIRT3 (mitochondrial deacetylase) requires NAD+ for activity; its inactivation leads to hyperacetylation of superoxide dismutase 2 (SOD2-K68) and dynamin-related protein 1 (DRP

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Skeptic's Critical Review

Hypothesis 1: SIRT3-Mediated Mitochondrial NAD+ Depletion Drives Distal Axon Degeneration

Strongest Specific Weakness

The chain of causation from "lactate transport" to "SIRT3 NAD+ depletion" contains an unjustified leap: it assumes neuronal NAD+ pools are primarily replenished by pyruvate oxidation derived from axonal lactate, and that this pool is sensitive enough to inhibit SIRT3. This ignores robust neuronal NAD+ salvage pathways (NAMPT-mediated) that can maintain NAD+ levels independently of mitochondrial respiration.

Counter-Evidence

  • **NAMPT
  • 🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

    Domain Expert Assessment: MCT1 Disruption Mechanisms in Neurodegeneration

    Preamble

    The Lee et al. (2012) framework established that oligodendroglial MCT1 is non-negotiable for axonal survival, but the downstream cascade remains one of the most consequential unknowns in metabolically driven neurodegeneration. Your Theorist's SIRT3 hypothesis is mechanistically sophisticated but—per the Skeptic's critique—has significant translational liabilities. Let me offer a frank assessment.

    1. Top Translational Hypotheses

    Rank 1: Neuronal NAD+ Depletion via NAMPT Dysregulation → Sirt

    Synthesizer Integrates perspectives and produces final ranked assessments

    {
    "ranked_hypotheses": [
    {
    "rank": 1,
    "title": "SIRT3/SOD2-DRP1 Hyperacetylation Links Lactate Transport Disruption to Distal Axon Degeneration",
    "mechanism": "MCT1 disruption impairs axonal lactate delivery, reducing neuronal NAD+ regeneration needed for SIRT3 activity, leading to hyperacetylation of SOD2-K68 and DRP1 and consequent oxidative stress and mitochondrial fission.",
    "target_gene": "SIRT3",
    "confidence_score": 0.60,
    "novelty_score": 0.70,
    "feasibility_score": 0.40,
    "impact_score": 0.80,
    "composite_score": 0.66,
    "te

    Price History

    0.550.590.64 created: post_process (2026-04-14T01:53)evidence: evidence_update (2026-04-14T01:53)evidence: evidence_update (2026-04-14T01:53) 0.69 0.50 2026-04-142026-04-142026-04-15 Market PriceScoreevidencedebate 7 events
    7d Trend
    Falling
    7d Momentum
    ▼ 0.8%
    Volatility
    High
    0.0534
    Events (7d)
    7
    ⚡ Price Movement Log Recent 3 events
    Event Price Change Source Time
    📄 New Evidence $0.610 ▼ 8.8% evidence_update 2026-04-14 01:53
    📄 New Evidence $0.669 ▲ 9.7% evidence_update 2026-04-14 01:53
    Listed $0.610 post_process 2026-04-14 01:53

    Clinical Trials (0)

    No clinical trials data available

    📚 Cited Papers (8)

    Paper:25352062
    No extracted figures yet
    Paper:27671644
    No extracted figures yet
    Paper:31689415
    No extracted figures yet
    Paper:33406435
    No extracted figures yet
    Paper:33440165
    No extracted figures yet
    Paper:39048544
    No extracted figures yet
    Paper:41512034
    No extracted figures yet
    Paper:41576094
    No extracted figures yet

    📓 Linked Notebooks (0)

    No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

    ⚔ Arena Performance

    No arena matches recorded yet. Browse Arenas
    → Browse all arenas & tournaments

    KG Entities (3)

    PVALB, SLC16A1/MCT1SARM1, NMNAT2neurodegeneration

    Related Hypotheses

    SASP-Mediated Complement Cascade Amplification
    Score: 0.703 | neurodegeneration
    TREM2-Dependent Microglial Senescence Transition
    Score: 0.692 | neurodegeneration
    H2: Indole-3-Propionate (IPA) as the Actual Neuroprotective Effector
    Score: 0.675 | neurodegeneration
    Nutrient-Sensing Epigenetic Circuit Reactivation
    Score: 0.670 | neurodegeneration
    Transcriptional Autophagy-Lysosome Coupling
    Score: 0.665 | neurodegeneration

    Estimated Development

    Estimated Cost
    $0
    Timeline
    0 months

    🧪 Falsifiable Predictions

    No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

    Knowledge Subgraph (2 edges)

    promoted: Parvalbumin Interneuron Vulnerability Links Lactate Transport to Gamma Oscillation Dysfunction (1)

    PVALB, SLC16A1/MCT1 neurodegeneration

    promoted: SARM1-Mediated NAD+ Depletion as Terminal Executor of MCT1-Dependent Axon Degeneration (1)

    SARM1, NMNAT2 neurodegeneration

    3D Protein Structure

    🧬 SARM1 — Search for structure Click to search RCSB PDB
    🔍 Searching RCSB PDB for SARM1 structures...
    Querying Protein Data Bank API

    Source Analysis

    What is the molecular mechanism by which oligodendroglial MCT1 disruption causes axon damage and neuron loss?

    neurodegeneration | 2026-04-13 | failed